ASXNSB Patented Stem Cell Solutions for Complex Auto-Immune Disorders & Unmet Needs August 2025 TechKnow Invest Roadshow Nathan Smith – Chief Executive Officer 1 For personal use only Disclaimers For personal use only Presentation Information This presentation has been prepared by NeuroScientific Biopharmaceuticals Ltd (ASX: NSB) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information nece ...

Core Insights - ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady, announced the awarding of $665,000 in G-Rex Grant funding to three investigators at the University of Minnesota's Center for Genome Engineering [1] Funding Details - Dr. Branden Moriarity received a $300,000 G-Rex Grant for a novel hyper-functional CAR NK cell therapy targeting advanced epithelial ovarian cancer in a Phase 1 clinical trial [2] - Dr. Beau Webber was awarded $240,000 for preclinical development of a novel TIL therapy for various solid tumors [3] - Dr. Joseph Skeate received $125,000 to support process development for TPP1 expressing T cells therapy for Batten Disease [4] Industry Impact - The G-Rex Grant Program has surpassed $40 million in no-cost product commitments aimed at advancing cell and gene-modified cell therapy development and manufacturing [7] - ScaleReady's G-Rex manufacturing platform is utilized by over 800 organizations, producing drug products for approximately 50% of CGT clinical trials and five commercially approved CGT drugs [10] Additional Initiatives - ScaleReady introduced a free program called LEAN Cell & Gene™ to help CGT entities improve efficiency and quality in manufacturing [8]